Harness patent attorney Kisuk Lee was quoted in an article published by Politico’s Prescription Pulse, “Lawmakers Press FDA on Clinical Trial Holds.”
The piece discussed the recent United States Supreme Court case hearing in Amgen v. Sanofi in which justices are being asked to determine whether Amgen’s patent for cholesterol-lowering antibodies is too broad. The lawsuit could have widespread impacts on patent law, not only on drugmakers but also possibly other corporate patent holders, but it is difficult to tell how the court is leaning, according to Lee.
“It’s hard to tell; the Supreme Court was quite neutral,” Lee told Prescription Pulse. One possible outcome is that the court proposes a new way of assessing whether a patent enables a person or a company to make and use an invention, he said.
To learn more, you may view the full article here.
Harness IP is celebrating more than 100 years as an intellectual property law firm. Founded in 1921, the firm currently holds a No. 2 ranking from IAM Media for providing counsel to 44 companies with the largest portfolios of issued U.S. patents. The firm also ranks No. 6 for filing the most patent applications on behalf of those companies. Harness IP’s attorneys and IP professionals focus exclusively on patents, trademarks, global IP management, litigation and other IP rights. The firm has offices in metropolitan Dallas, Detroit, St. Louis, and Washington, D.C. Visit www.harnessip.com for more information.